---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-003777"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-05-22T23:59:59+00:00"
generated_at: "2026-06-01T09:41:13.777353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma Q1 2024 revenue up 54% to $7.54M; net loss narrows to $1.28M

## Summary
- Q1 2024 revenue of $7,541,046, a 54% increase from $4,894,053 in Q1 2023.
- Net loss of $(1,283,801) improved from $(1,702,430) in the prior-year quarter.
- Gross profit rose to $2,354,337 from $1,828,122, driven by new product launches.
- In February 2024, completed public offering for gross proceeds of ~$10 million.
- Growth attributed to expanded sales efforts by subsidiary Nora Pharma Inc.

## SEC filing metadata
- accession: 0001683168-24-003777
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-05-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824003777/0001683168-24-003777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824003777/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-003777
- JSON: https://secwatch.observer/filing/0001683168-24-003777.json
- Plain text: https://secwatch.observer/filing/0001683168-24-003777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.